

Additional supplemental

material is published online

the journal online (http://dx.

doi.org/10.1136/bjo-2023-

For numbered affiliations see

Correspondence to

Belfast, Belfast, UK;

Professor Augusto Azuara-

Queen's University Belfast,

a.azuara-blanco@qub.ac.uk

Received 29 March 2023 Accepted 13 October 2023

Blanco, Centre for Public Health,

323648).

end of article.

only. To view, please visit

# European Glaucoma Society research priorities for glaucoma care

Augusto Azuara-Blanco (1), <sup>1</sup> Noleen McCorry, <sup>1</sup> Andrew J Tatham (1), <sup>2</sup> Stelios Georgoulas (1), <sup>3</sup> Panayiota Founti, <sup>4</sup> Cedric Schweitzer, <sup>5</sup> Frances Meier-Gibbons (1), <sup>6</sup> Philippe Denis, <sup>7</sup> Anja Tuulonen, <sup>8</sup> Gauti Johannesson, <sup>9</sup> José María Martínez de la Casa (1), <sup>10</sup> Verena Prokosch, <sup>11</sup> Dimitrios A Giannoulis (1), <sup>12</sup> Luis Abegão Pinto, <sup>13</sup> David Garway-Heath, <sup>14</sup> Fotis Topouzis<sup>12</sup>

# ABSTRACT

**Background/Aims** The goal of health research is to improve patients care and outcomes. Thus, it is essential that research addresses questions that are important to patients and clinicians. The aim of this study was to develop a list of priorities for glaucoma research involving stakeholders from different countries in Europe.

**Methods** We used a three-phase method, including a two-round electronic Delphi survey and a workshop. The clinician and patient electronic surveys were conducted in parallel and independently. For phase I, the survey was distributed to patients from 27 European countries in 6 different languages, and to European Glaucoma Society members, ophthalmologists with expertise in glaucoma care, asking to name up to five research priorities. During phase II, participants were asked to rank the questions identified in phase I using a Likert scale. Phase III was a 1 day workshop with patients and clinicians. The purpose was to make decisions about the 10 most important research priorities using the top 20 priorities identified by patients and clinicians.

**Results** In phase I, 308 patients and 150 clinicians were involved. In phase II, the highest-ranking priority for both patients and clinicians was 'treatments to restore vision'. In phase III, eight patients and four clinicians were involved. The top three priorities were 'treatments to stop sight loss', 'treatments to restore vision' and 'improved detection of worsening glaucoma'.

**Conclusion** We have developed a list of priorities for glaucoma research involving clinicians and patients from different European countries that will help guide research efforts and investment.

## INTRODUCTION

Check for updates

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Azuara-Blanco A, McCorry N, Tatham AJ, et al. Br J Ophthalmol Epub ahead of print: [please include Day Month Year]. doi:10.1136/ bjo-2023-323648 Glaucoma is among the leading causes of vision impairment in Europe and, in the recent past, we have seen the incorporation of technologies that aim to improve glaucoma care.<sup>1</sup> However, there are many questions regarding glaucoma management (eg, diagnosis, evaluation of risk, treatment, models of eye care) that remain unanswered.

The ultimate goal of health research is to improve patient care and outcomes. Thus, it is essential that research addresses questions that are important to patients and clinicians, and that the limited research funds are directed towards to these priorities.<sup>2–4</sup> Priority-setting initiatives including patients and clinicians can influence the direction of future

# WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Identification of research priorities needs to involve relevant stakeholders.

#### WHAT THIS STUDY ADDS

⇒ The top 10 research priorities for glaucoma have been identified.

# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study will influence future research strategies and funding opportunities.

research and funding at the policy, institutional and research team levels.<sup>5</sup> <sup>6</sup> Examples of pioneer priority-setting partnerships were between Asthma UK and the British Thoracic Society.<sup>7</sup> Addressing topics or relevance to patients and clinicians help reduce research waste, as highlighted by Chalmers *et al.*<sup>8</sup>

The aim of this study was to develop a list of priorities for glaucoma research involving clinicians and patients from different countries in Europe. This initiative was supported by the European Glaucoma Society (EGS).

## MATERIALS AND METHODS

A Steering Group was created among members of the EGS Scientific and Outcomes Committees. The purpose of the steering committee was to develop a protocol and facilitate work. We used a three-phase method, including a two-round electronic Delphi survey and a workshop (figure 1).<sup>9 10</sup> The clinician and patient electronic surveys were conducted by email, in parallel and independently.

#### Phase I: electronic survey to identify patient and clinician research priorities

Patient organisations in Europe were identified through a process of peer knowledge and consultation among the Steering Group members' networks. Patients were also approached directly by their attending glaucoma specialist when attending a clinic to answer the survey. In phase I, patients were contacted by email or by supporting staff in the clinic waiting area and were asked a series of questions regarding their demographics, glaucoma



Figure 1 Flow chart describing phases of the study. Phases I and II were done in parallel among patients and glaucoma experts, independently.

treatment, perception of glaucoma care and research priorities. The survey was distributed to patients from 27 European countries from 3 to 24 May 2022. The survey consists of 23 questions divided into 3 sections. The survey was translated into six languages: English, French, German, Spanish, Portuguese and Greek.

Regarding the clinicians research priorities, the invited participants were EGS members, ophthalmologists with expertise in glaucoma care. The survey was sent to active and emeritus members (total n=788).

Submitted research questions were translated (if not in English language) and analysed by steering committee members (AT, PF). Text mining was performed to identify the most frequently used keywords from the translated patient responses. A frequency of word table and word cloud were generated. Similarly, themed responses were then merged by the two steering committee members to ensure the meaning of the priorities was not distorted. The steering committee members initially worked independently and then for cases of disagreement reached a consensus on categorisation of each priority. No limit was placed on the number of research priorities each patient could suggest and all were included in the analysis. A similar process was followed for merging similarly themed responses obtained from the EGS member survey. All analyses were performed using R Studio (V.12.0, RStudio, PBC, Boston, Massachusetts, USA).

# Phase II: electronic survey to rank patient and clinician research priorities

During phase II, EGS members and patients were invited, via email, to rank the questions identified in phase I using a Likert scale from 1 (lowest research priority) to 5 (highest research priority). Two reminders were sent via email over a 4-week period.

The steering committee reviewed the results. The mean rank score of the research priorities was calculated. Common and similar research priorities between clinicians and patients were merged but keeping the original description. The top 20 research priorities from both cohorts were selected. Similar questions were merged ensuring that the meaning of the questions was not distorted and keeping the original description to produce the top 20 joint research priorities carried forward to phase III.

# Phase III: meeting with patients and clinicians to reach consensus on top 10 priorities

The final priority setting stage (phase III) was a 1 day workshop in Lisbon on 30 September 2022 facilitated by an expert researcher (NMcC). The purpose of the workshop was to exchange knowledge and to make decisions about the most important research priorities, based on the wide set of experiences represented by the workshop participants, using an adapted Nominal Group Technique (NGT). NGT is appropriate when small groups want to make decisions within a limited period of time. The technique allows for consideration of everyone's opinions through discussion and can incorporate both ranking and voting exercises. Participants were informed that the outcomes from the workshop would be shared with researchers and research funders. Eight patients and four clinicians from different European countries able to communicate well in English participated in the workshop. We tried to have a wide range of ages and gender balance among patients. In addition, there were two observers (current EGS President and EGS chair of European Union Committee) who did not participate in the discussions/rankings. The goal was to determine and rank the top 10 questions for research. All participants declared their interests. The role of the facilitator was to supervise group dynamics to ensure that all participant voices were heard and considered, to encourage debate and transparency and to help draw participants to consensus.

Before the workshop, participants were required to complete a 'preworkshop exercise', where they reviewed the 20 shortlisted priorities identified by phase II. They were instructed to order these priorities from '1' (most important area for research in your opinion) to '20' (least important area for research in your opinion). At the workshop, following a short presentation and introduction, each participant was given the opportunity to share their 'top 3' and 'bottom 3' priorities with the group, and to explain the reasons for their rankings. These were noted by the facilitator. This completed the first part of the workshop. During a break, the workshop facilitator identified those priorities that were most often cited within the 'top 3' and 'bottom 3' by participants and arranged these in rough groups across a large table (using A4 cards printed with each priority, A-T). Other cited priorities, or those not mentioned by any participant, were arranged in a middle group. Participants then discussed the priorities and their order, until the



Figure 2 Word cloud (A) and bar chart (B) showing most frequent words used by patients responding to research priority question in phase I.

top 10 priorities were ranked in order. On two occasions, a vote was taken to decide between the order of two priorities. The workshop discussions were recorded, with permission of participants.

# RESULTS

#### Phase I

Of 402 patients from 20 European countries answering the questionnaire, 308 proposed one or more research priorities. One hundred fifty-one of 308 respondents (49.0%) were from the UK, 75 (24.4%) from France, 20 (6.5%) from Germany, with the remainder from other European countries. Of those proposing a research priority, 190 (61.7%) were female. Respondents' age range was diverse, with 33 of 308 (10.7%)  $\leq$ 49 years, 51 (16.7%) between 50 and 59 years, 87 (28.2%) between 60 and 69 years, 104 (33.8%) between 70 and 79 years and 33 (10.7%) 80 years or older. Two hundred twenty-eight (74.0%) were currently being treated with ocular hypotensive eye drops, 135 (43.8%) had undergone laser treatment for glaucoma and 132 (42.9%) had undergone glaucoma surgery. The most frequent words used by patients to describe the research priorities most important to them are summarised in figure 2.

The most commonly cited research priorities related to improving screening and early diagnosis (51 of 308, 16.6%), followed by treatments to restore vision (47 of 308, 15.3%), better ways to stop sight loss (32 of 308, 10.4%), improved understanding of risk factors for sight loss (32 of 308, 10.4%), better treatments (27 of 308, 8.8%), drops with fewer side effects (19 of 308, 6.2%) and improved resources for patient education and self-help (23 of 308, 7.5%) (figure 3).

A total of 150 clinicians proposed one or more research priorities. The priorities most commonly proposed by clinicians were neuroprotection (66 of 150, 44%), improved or better evidence for minimally invasive glaucoma surgery (39, 26%), improved treatments (34, 22.7%), screening, early diagnosis and avoiding late diagnosis (29, 19.3%), improved surgical treatments (29, 19.3%), better tools to detect progression and those at high risk of progression (28, 18.7%), sustained release and longer acting treatments (28, 18.7%), new medical treatments (27, 18%), artificial intelligence (26, 17.3%) and treatments to restore vision (25, 16.7%) (figure 4).

# Phase II

A total of 279 patients provided email contact details and were invited to participate in phase II. A total 111 of 279 responded (39.8% response rate), including 61 responding to the English language survey, 5 to the Spanish survey, 25 to the German survey and 20 to the French survey.

Patient and clinician round 2 scores are summarised in online supplemental appendix 1. The highest-ranking priority was treatments to restore vision (mean score 4.50), followed by better ways to stop sight loss (mean score 4.48), finding a cure (mean score 4.40), improved detection of worsening glaucoma (mean score 4.36), development of treatments to avoid need for eye drops (mean score 4.22) and better ways to avoid surgery (mean score 4.16).

A total of 147 clinicians provided their email details and were invited to participate in phase II; 65% (96 of 147) clinicians responded. Clinicians assigned the highest scores to research priorities; better tools to detect progression and risk of rapid progression (mean score 4.31), improved surgical treatments (mean score 4.18), stopping progression of glaucoma (mean score 4.12), improved management of advanced glaucoma (mean score 4.08), improved evidence for current surgical treatments (mean score 4.05) and neuroprotection (mean score 3.99) (online supplemental appendix 1).

The top 20 priorities scored by clinicians and patients are summarised in figure 4.

## Phase III

In phase III, patients (n=8) were from the following countries: the UK (n=3), France, Germany, Portugal, Sweden and Norway. There were five females and three males. Clinicians were from the UK (n=3) and Finland, with three males and one female.

Table 1 presents the agreed top 10 priorities for research that followed discussion during the workshop. Workshop attendees proposed that the following considerations should be taken into account when defining research priorities:

- ► The priority 'finding a cure' as an overall encompassing goal.
- The importance of 'improving quality of life' for people with glaucoma
- The priority 'artificial intelligence in glaucoma management' as a tool to achieve other priorities.



**Figure 3** Top: frequency of research priorities proposed by patients responding to phase I. Bottom: frequency of research priorities proposed by clinicians responding to phase I.

Priority #1 ('better ways to stop sight loss/stopping progression of glaucoma') includes (but may not be limited to) priorities 4, 6 and 7.

#### DISCUSSION

We have reported the results of a European-wide effort to establish the top 10 priorities for research in glaucoma. Our process has aimed at reflecting the priorities of patients and clinicians. Although we observed some overlap in topics, an important finding of our process is that patients and doctors have different priorities. For example, finding a cure was a top research priority by patients but not identified as such by doctors, possibly due to feasibility considerations. Patients' priorities not shared by doctors included novel treatments to avoid the need for eye drops and to avoid surgery, and interventions to keep patients' independence. Doctors' priorities not considered important by patients included modulation of wound healing and the use of artificial intelligence.

In the final workshop, the two most important research priorities (treatments to stop sight loss and treatments to restore vision) were the ones identified by patients, reflecting the larger importance of patients' voice. Some of the top 10 research priorities identified by clinicians (eg, use of artificial intelligence, improved modulation of wound healing) were not included in the final top 10 list after phase III discussions.

Frequency

The strengths of this study are that it followed the robust standard methodology, and that we included a fairly large number of clinicians and patients from different European countries.<sup>11</sup> Modified electronic Delphi process is commonly used to reach consensus and identify research priorities in diverse health areas.<sup>12-16</sup>

Several frameworks have been used to guide the process of priority setting, including the James Lind Alliance Priority Setting Partnership (JLA PSP),<sup>17</sup> Essential National Health Research (ENHR)<sup>18</sup> and the Dialogue Model.<sup>19</sup> The JLA PSP method convenes patients, carers and clinicians to equally and jointly identify questions about healthcare that cannot be answered by existing evidence that are important to all groups (ie, research needs).<sup>17</sup> The identified research needs are then prioritised by the groups resulting in a final list (often a top 10) of research priorities. Non-clinical researchers are excluded from voting on research needs or priorities but can be involved in other processes (eg, knowledge synthesis). The ENHR method, initially designed for health research priority setting at the national level, involves

Priority ID	Research priority	Ranking by patients and doctors <mark>(yellow</mark> highlight for patients)	Priority ID	Research priority	Ranking by patients and doctors <mark>(yellow</mark> highlight for patients)
Α	Treatment to restore vision / Treatments to restore vision	<mark>#1 by patients</mark> #11 by doctors	к	Treatments with fewer side effects / Treatments with fewer side effects	<mark>#9 by patients</mark> #17 by doctors
В	Better ways to stop sight loss / Stopping progression of glaucoma	<mark>#2 by patients</mark> #3 by doctors	L	Improved diagnostic tests /	#10 by patients
С	Finding a cure	#3 by patients	м	Improved visual field tests / Novel or improved methods of imaging	16 by patients #16 by doctors
D	Improved detection of worsening glaucoma better tools to detect progression and risk of rapid progression	<mark>#4 by patients</mark> #1 by doctors	N	Better understanding of what causes glaucoma and risk factors / Genetics of glaucoma	#11 and #12 by patients
E	Development of treatments to avoid the need for eye drops	#5 by patients	0	Better surgical or laser treatments Improved surgical treatments Improved evidence for current surgical treatments Improved MIGS or better evidence for MIGS	<mark>#14 by patients</mark> # 2, 5, and 14 by doctors
F	Better ways to avoid surgery	# 6 by patients	Р	Improved modulation of wound healing	#7 by doctors
G	Methods to treat glaucoma other than by lowering intraocular pressure / Neuroprotection and non-IOP treatments	# 17 by patients # 5 by doctors	Q	Screening, early diagnosis, avoiding late diagnosis	<mark>#18 by patients</mark> # 10 by doctors
Н	Better medical treatment / New medical treatments	<mark>#7 by patients</mark> #8 by doctors	R	Treatments to keep patients independent	<mark>#8 by patients</mark>
I	Longer lasting sustained release medications / Sustained release and longer acting treatments	<mark># 19 by patients</mark> # 18 by doctors	S	Improved management of advanced glaucoma	#4 by doctors
J	Treatments to keep patients independent	<mark>#8 by patients</mark>	т	Artificial intelligence in glaucoma management	#9 by doctors

Figure 4 Top 20 research priorities identified in phase II according to clinicians and patients (highlighted in yellow). MIGS, minimally invasive glaucoma surgery.

researchers, decision-makers, health service providers and communities throughout the entire process of identifying and prioritising research topics.<sup>18</sup>

This study has some limitations. First, the response rate among clinicians was low and thus may not be representative. It is possible a different design of the electronic survey or incentives may have improved the response rate. The patients who volunteered to participate in the survey may not be representative of the wider population of people with glaucoma. There may be an over-representation of patients with history of glaucoma surgery and presumably with severe stage of the disease, which may explain that the top research priority is 'treatment to restore vision'. However, this was also among the top 20 priorities for clinicians which confirms the importance of this topic. The clinicians' different preference is probably based on the understanding that the glaucoma damages are not reversible and research in this area will take a long time to be translated in improved outcomes. There was also a bias towards patients from the UK and France, with fewer patients included from

Table	1 Top 10 research priorities identified in phase III
	Priority/Uncertainty
1.	Better ways to stop sight loss/stopping progression of glaucoma.
2.	Treatments to restore vision.
3.	Improved detection of worsening glaucoma/better tools to detect progression.
4.	New/Better medical treatments.
5.	Better understanding of what causes glaucoma and risk factors/genetics of glaucoma.
6.	Better surgical or laser treatments including improved MIGS or better evidence for MIGS.
7.	Methods to treat glaucoma other than lowering IOP/neuroprotection and non-IOP treatments.
8.	Improved diagnostic tests including 8(a) improved visual field tests/novel or improved methods of imaging.
9.	Screening, early diagnosis, avoiding late diagnosis.
10.	Treatments with fewer side effects.
MIGS, m	inimally invasive glaucoma surgery.

other European countries. It is conceivable that differences in socioeconomic status, ethnicity, health beliefs, mode of healthcare provision and other factors could result in different priorities. Nevertheless, the research priorities identified in this study cover broad topics and to the best of our knowledge this was first attempt to identify research priorities in glaucoma across Europe.

In conclusion, the results of this study can be used to guide research funding bodies and the wider research community in advancing the quality of care for patients with glaucoma. An effort to identify specific research questions and define study designs (population, intervention, comparator, outcome) to address the identified research priorities is currently under way.

#### Author affiliations

<sup>1</sup>Centre for Public Health, Queen's University Belfast, Belfast, UK

<sup>2</sup>Ophthalmology Department, Princess Alexandra Eye Pavilion, Edinburgh, UK<sup>3</sup>Ophthalmology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

<sup>4</sup>Glaucoma Service, Moorfields Eye Hospital City Road Campus, London, UK <sup>5</sup>Ophthalmology, University Hospital Centre Bordeaux, Bordeaux, France

<sup>6</sup>Ophthalmology, University Hospital Centre Bordeaux, Bordeaux, <sup>6</sup>Ophthalmology, Eye Center Rapperswil, Rapperswi, Switzerland

<sup>7</sup>Service d'Ophtalmologie, Hôpital Universitaire de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France

<sup>8</sup>Tays Eye Centre, Tampere University Hospital, Tampere, Finland

<sup>9</sup>Department of Clinical Sciences, Ophthalmology, Umeå University, Umea, Sweden <sup>10</sup>Ophthalmology, Hospital Clinico San Carlos, Madrid, Spain

<sup>11</sup>Department of Ophthalmology, University of Cologne, Koln, Germany <sup>12</sup>First Department of Ophthalmology, School of Medicine, Faculty of Health Sciences,

Aristotle University of Thessaloniki, Thessaloniki, Greece <sup>13</sup>Department of Ophthalmology, Santa Maria Hospital, University of Lisbon, Lisboa,

Portugal

<sup>14</sup>Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK

Twitter Augusto Azuara-Blanco @AAzuaraBlanco

**Acknowledgements** We would like to thank all patients and clinicians who participated in this process and, in particular, Sarah Tayler, Asle Haukaas, Fernando Carvalhao, Deb Davidson, Kate Backhaus, Steven Tsui, Mona Krieg and Carol Bronze for their participation in phase III. We would like to thank Dr Ayla Basasoro Garmendia for the initial analyses of phase I survey answers.

**Contributors** All authors made substantial contributions to the conception or design of the work; the acquisition, analysis or interpretation of data for the work; drafting the work and revising it critically for important intellectual content; approved the final version to be published and agreed to be accountable for all

# **Clinical science**

aspects of the work. AAB is the guarantor and accepts full responsibility of the conduct and data of the study.

Funding This study was supported by the European Glaucoma Society.

Competing interests None declared.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

**Data availability statement** Data sharing not applicable as no datasets generated and/or analysed for this study.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### ORCID iDs

Augusto Azuara-Blanco http://orcid.org/0000-0002-4805-9322 Andrew J Tatham http://orcid.org/0000-0003-0372-3100 Stelios Georgoulas http://orcid.org/0000-0002-7009-0908 Frances Meier-Gibbons http://orcid.org/0000-0002-3158-5641 José María Martínez de la Casa http://orcid.org/0000-0001-9441-0542 Dimitrios A Giannoulis http://orcid.org/0000-0002-7795-2152

#### REFERENCES

- 1 Gallo Afflitto G, Aiello F, Cesareo M, et al. Primary open angle glaucoma prevalence in Europe: a systematic review and meta-analysis. J Glaucoma 2022;31:783–8.
- 2 Partridge N, Scadding J. The James LIND alliance: patients and clinicians should jointly identify their priorities for clinical trials. *Lancet* 2004;364:1923–4.
- 3 Oliver S, Clarke-Jones L, Rees R, et al. Involving consumers in research and development agenda setting for the NHS: developing an evidence-based approach. *Health Technol Assess* 2004;8:1–148.

- 4 O'Donnell M, Entwistle V. Consumer involvement in decisions about what healthrelated research is funded. *Health Policy* 2004;70:281–90.
- 5 Staley K, Crowe S, Crocker JC, et al. What happens after James LIND alliance priority setting partnerships? A qualitative study of contexts, processes and impacts. *Res Involv Engagem* 2020;6:41.
- 6 Oliver S, Armes DG, Gyte G. Public involvement in setting a national research agenda: a mixed methods evaluation. *Patient* 2009;2:179–90.
- 7 Elwyn G, Crowe S, Fenton M, *et al.* Identifying and Prioritizing uncertainties: patient and clinician engagement in the identification of research questions. *J Eval Clin Pract* 2010;16:627–31.
- 8 Chalmers I, Bracken MB, Djulbegovic B, et al. How to increase value and reduce waste when research priorities are set. *The Lancet* 2014;383:156–65.
- 9 Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376–80.
- 10 Jones J, Hunter D. Using the Delphi and nominal group technique in health services research. In: Pope C, Mays N, eds. *Qualitative Research in Health Care*. London: BMJ Books, 2000: 132–41.
- 11 Yoshida S. Approaches tools and methods used for setting priorities in health research in the 21(St) century. *J Glob Health* 2016;6:010507.
- 12 Bretherton CP, Claireaux HA, Gower J, et al. Research priorities for the management of complex fractures: a UK priority setting partnership with the James LIND alliance. BMJ Open 2021;11:e057198.
- 13 Scrimgeour DSG, Allan M, Knight SR, et al. Scottish surgical research group and the British hernia society. A modified Delphi process to establish research priorities in hernia surgery. *Hernia* 2021;31:1–9.
- 14 Cathie K, Sutcliffe AG, Bandi S, et al. Priorities for child health research across the UK and Ireland. Arch Dis Child 2022;107:474–8.
- 15 Etti M, Alger J, Salas SP, et al. Newborn and child health working group of the COVID-19 clinical research coalition. global research priorities for COVID-19 in maternal, reproductive and child health: results of an international survey. *PLoS One* 2021:e0257516.
- 16 Nyanchoka L, Tudur-Smith C, Thu VN, et al. A Scoping review describes methods used to identify. Prioritize and Display Gaps in Health Research J Clin Epidemiol 2019;109:99–110.
- 17 James Lind Alliance. The James Lind Alliance Guidebook, March . 2020Available: http://www.jla.nihr.ac.uk/jla-guidebook/downloads/JLA-Guidebook-V9-download-March-2020.pdf
- 18 Montorzi G, Haan S, Ijsselmuiden C. Priority setting for research for health. A management process for countries. In. Durban: council on health research for development, 2010.
- 19 Abma TA, Broerse JEW. Patient participation as dialogue: setting research Agendas. *Health Expect* 2010;13:160–73.

# EGS Research Priorities Delphi Survey - Round 2 Results Summary

## **Response rates**

OPEN	Glaucoma research priorities for patients - French Design Distribute Analyse	v1atatha@ed.ac.uk	20 of 68 (29%)	24 Aug 2022	1 Oct 2022	8 DAYS LEFT
OPEN	Glaucoma research priorities for patients - German Design Distribute Analyse	v1atatha@ed.ac.uk	25 of 46 (54%)	24 Aug 2022	1 Oct 2022	8 DAYS LEFT
OPEN	Glaucoma research priorities for patients - Spain Design Distribute Analyse	v1atatha@ed.ac.uk	5 of 18 (27%)	24 Aug 2022	1 Oct 2022	8 DAYS LEFT
OPEN	Glaucoma research priorities for patients Design Distribute Analyse	v1atatha@ed.ac.uk	61 of 147 (41%)	24 Aug 2022	1 Oct 2022	8 DAYS LEFT
OPEN	EGS research priorities round 2 Design Distribute Analyse	v1atatha@ed.ac.uk	97 of 147 (65%)	24 Aug 2022	23 Sep 2022	

279 patients provided email and were invited to participate in round 2. 111 responded (39.8% response rate), including 61 responding to the English language survey, 5 to the Spanish survey, 25 to the German survey and 20 to the French survey.

147 clinicians provided their email and were invited to participate in round 2. 65% responded. 2 reminder emails were sent, only to those who did not respond to the initial email.

For round 2 patients were asked to score each research priority from 1 (least important) to 5 (most important).

# Clinician Round 2 scores (0 to 5, with 5 being very important)

Better tools to detect progression and risk of rapid progression4.30278Improved surgical treatments4.175288Stoppin progression of glaucoma4.02471Improved ranagement of advanced glaucoma4.02474Improved radidence for current surgical treatments3.99691Improved modulation of wound healing3.979381New medical treatments3.969072Artificial Intelligence in glaucoma management3.915026Screening entry diagnosis avoiding late diagnosis3.865028Improved evidence for current treatments3.835028Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.721649Nevel or improved methods of inaging3.711400Treatments with fewer side effects3.60701Sustained release and longer acting treatments3.597381Avoid or improved methods of inaging3.578703Storting overtreatment3.587703Glaucoma revision surgery3.538622Glaucoma revision surgery3.538703Storting outcrease3.525773Improved understanding or interatments or devolopment of new laser3.525773Improved vidence for rurent laser treatments or devolopment of new laser3.525773Improved vidence for current laser treatments or devolopment of new laser3.525773Improved understanding or integration of structure and function tests3.463918Tabacular methwork regeneration3.422649Improved evidence for current laser treatments or devolopment of new laser3.52773Improved evide	Priority	Mean
Improved surgical treatments4.175288Biopping progression of glaucoma4.123711Improved management of advanced glaucoma4.082474Improved modulation of wound healing3.998017Neuroprotection and non IOP treatments3.980017Artificial intelligence in glaucoma management3.915265Screening early diagnosis avoiding late diagnosis3.880001Improved modulation of wound healing3.815265Screening early diagnosis avoiding late diagnosis3.880001Improved reduce for current treatments3.815001Glaucoma registers and real world data3.174301Improved prediction of response to treatment3.71449Novel or improved methods of imaging3.711401Treatments with fewer side effects3.670010Sustained release and longer acting treatments3.687010Glaucoma revision surgary3.558001Stating appropriate treatment targets3.567010Glaucoma revision surgary3.558010Inproved understanding or integration of structure and function tests3.47281Inproved nethods of Inogener3.27181Scientific Treatments for angle closure3.27181Inproved and functioning3.371814Inproved and fu	Better tools to detect progression and risk of rapid progression	4.309278
Stopping progression of glaucoma4.123711Improved management of advanced glaucoma4.082474Improved evidence for current surgical treatments3.09012Artificial intelligence in glaucoma management3.990321Artificial intelligence in glaucoma management3.980598Improved evidence for current treatments3.880598Improved methods of imaging3.711409Treatments to restoro vision3.870598Improved methods of imaging3.711409Treatments with fewer side effects3.670109Sustained release and longer acting treatments3.587291Quality of life evaluation and improvement3.587291Glaucoma revision surgery3.580291Improved understanding or ink factors3.58711Better evidence for current laser treatment sord social so	Improved surgical treatments	4.175258
Improved management of advanced glaucoma4.082474Improved evidence for current surgical treatments4.051546Neuroportection and not DP treatments3.989911Improved modulation of wound healing3.989911New medical treatments3.989072Artificial intelligence in glaucoma management3.81558Improved evidence for current treatments3.855082Treatments to restore vision3.815082Olaucoma registers and real world data3.814333Improved prediction of response to treatment3.714494Novel or improved methods of imaging3.711340Treatments with fewer side effects3.607012Sutalined release and longer acting treatments3.587703Avoiding overtreatment3.587703Glaucoma registers and real world kators3.587703Sutalined release and longer acting treatments3.587703Glaucoma registers and real world stators3.587703Sutandrading outcomes3.587703Glaucoma resiston surgery3.586703Glaucoma resiston surgery3.586703Improved understanding of risk factors3.515640Identre vidence for current laser treatments or development of new laser3.412271Improved evidence for current laser treatments or development of new laser3.412271Improved understanding or integration of structure and function tests3.311430Tabcular meshwork regeneration3.412271Statabacel in and motoring3.321732Statabacel in adviser3.321732Glaucoma acting in structure for seconda	Stopping progression of glaucoma	4.123711
Improved evidence for current surgical treatments4.051546Neuroprotection and non IOP treatments3.989691Improved modulation of wound healing3.979381New medical treatments3.960072Artificial intelligence in glaucoma management3.835052Screening early diagnosis avoiding late diagnosis3.866078Improved vidence for current treatments3.835052Olaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.7762887Novel or improved methods of imaging3.7111340Treatments with fewer side effects3.50703Sutalined release and longer acting treatments3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Shadandishing outcomes3.557618Improved understanding or risk factors3.515464Ientresion surgery3.586618Better evidence for treatments for angle closure3.47227Improved evidence for current laser treatments or development of new laser3.291731Standardising training in glaucoma3.301753Guatoma for ind tratterion3.20287Standardising training in glaucoma3.301753Guatoma for ind treatments or development of new laser3.301753Standardising training in glaucoma3.301753Guatoma for ind treatments for ascondary glaucomas3.302763Standardising training in glaucoma3.301753Guatoma for ind treatme	Improved management of advanced glaucoma	4.082474
Neuroprotection and non IOP treatments3.989891Improved modulation of wound healing3.979831New medical treatments3.990972Artificial Intelligence in glaucoma management3.917528Screening early diagnosis avoiding late diagnosis3.886598Improved evidence for current treatments3.835002Treatments to restore vision3.814333Improved prediction of response to treatment3.711340Novel or improved methods of imaging3.711340Treatments with fewer side effects3.6870133Sustained release and longer acting treatments3.597033Avoiding overtreatment3.597033Auding overtreatment3.597033Glaucoma registors and registors3.567013Sustained release and longer acting treatments3.597033Avoiding overtreatment3.597033Glaucoma revision surgery3.508023Increasing public awareness3.557013Better evidence for treatments for angle closure3.471272Improved evidence for current laser treatments or development of new laser3.422693Improved evidence for current laser treatments or development of new laser3.301733Glaucins for low to middle income settings3.301733Sutainsing training in glaucoma3.301733Graetcus of glaucoma3.301733Graetcus of glaucoma3.301733Graetcus of glaucoma3.301733Guatomis for low to middle income settings3.302783Sutainable healthcare delivery3.302783Sutainable healthcare delivery	Improved evidence for current surgical treatments	4.051546
Improved modulation of wound healing3.979381New medical treatments3.969072Artificial intelligence in glaucoma management3.917526Screening early diagnosis avoiding late diagnosis3.886598Improved evidence for current treatments3.835052Treatments to restore vision3.835052Glaucoma registers and real world data3.114343Improved prediction of response to treatment3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597393Avoiding overtreatment3.587620Glaucoma revision surgery3.580682Increasing public avareness3.557701Glaucoma revision surgery3.580682Increasing public avareness3.557731Improved understanding or ints factors3.515464Identify causes of glaucoma3.60155Better evidence for treatments for angle closure3.4742272Improved understanding or intsgration of structure and function tests3.463918Trabecular meshwork regeneration3.422860Improved avasensemt of visual function3.302625Improved avasensemt of visual function3.302625Improved assessment of visual function3.302732Improved anderstanding of and treatments for aceondary glaucoma3.3711340Solutions for low to middle income settings3.3711341Improved assessment of visual function3.302678Genetics of glaucoma3.247732Improved assessment of visual function3.267732Improved	Neuroprotection and non IOP treatments	3.989691
New medical treatments3.969072Artificial intelligence in glaucoma management3.917526Screening early diagnosis avoiding late diagnosis3.885098Improved evidence for current treatments3.835052Glaucoma registers and real world data3.814433Improved floS or better evidence for MIGS3.762887Improved prediction of response to treatment3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597381Avoiding overtreatment3.597393Avoiding overtreatment3.597393Glaucoma revision surgery3.580601Glaucoma revision surgery3.580701Improved understanding or risk factors3.557701Improved understanding or integration of structure and function tests3.40311Trabecular meshwork regeneration3.422801Improved understanding or integration of structure and function tests3.412311Standardising runtegeneration3.422801Improved understanding or integration of structure and function tests3.412311Standardising runtegeneration3.422801Improved understanding or integration of structure and function tests3.391753Genetics of glaucoma3.3711341Standardising runting in glaucoma3.391753Genetics of of uso omitoring3.302674Standardising runting in glaucoma3.391753Genetics of glaucoma3.2917732Improved understanding of and treatments for secondary glaucomas3.392773Standardising runting in gla	Improved modulation of wound healing	3.979381
Artificial Intelligence in glaucoma management3.917526Screening early diagnosis avoiding late diagnosis3.886598Improved evidence for current treatments3.835052Treatments to restore vision3.835052Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.762887Novel or improved methods of imaging3.711340Treatments with fewer side effects3.507003Sustained release and longer acting treatments3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.556701Glaucoma revision surgery3.580622Increasing public awareness3.555771Improved understanding or integration of structure and function tests3.403818Trabecular meshwork regeneration3.422802Improved evidence for current laser treatments or development of new laser3.41134Improved assessment of visual function3.309753Solutions for low to middle income settings3.31134Improved assessment of visual function3.309278Solutions for low to middle income settings3.309772Sutainable healthcare delivery3.309278Sutainable healthcare delivery3.309278Sutainable healthcare delivery3.309278Sutainable healthcare dilucy3.257732Improving adherence and drop instillation3.257732Improving adherence and drop instillation3.257732Improving adheren	New medical treatments	3.969072
Screening early diagnosis avoiding late diagnosis3.886598Improved evidence for current treatments3.835052Teatments to restore vision3.835052Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.711340Treatments with fewer side effects3.67003Sustained release and longer acting treatments3.597938Avoiding overtreatment3.587629Quality of life evaluation and improvement3.597010Standardising outcomes3.567010Glaucoma revision surgery3.508022Increasing public awareness3.556701Glaucoma revision surgery3.508022Increasing outlic on integration of structure and function tests3.474227Improved understanding of risk factors3.412371Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371Standardising training in glaucoma3.391753Schudins for low to middle income settings3.371134Solutions for low to middle income settings3.391753Statainable healthcare delivery3.309278Sustainable healthcare delivery3.309278Sustainable healthcare delivery3.209278Sustainable healthcare delivery3.209278Sustainable healthcare delivery3.209278Sustainable healthcare delivery3.209278Sustainable healthcare delivery3.209278Sustainable healthcare de	Artificial intelligence in glaucoma management	3.917526
Improved evidence for current treatments3.835052Treatments to restore vision3.835052Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.721649Novel or improved methods of imaging3.7111340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.586701Glaucoma revision surgery3.5687629Improved understanding or integration of structure and function tests3.474227Improved understanding or integration of structure and function tests3.412371Standardising training in glaucoma3.301733Genetics of glaucoma3.301733Genetics of glaucoma3.301733Genetics of glaucoma3.301733Solutions for low to middle income settings3.371134Improved assessment of visual function3.60025Telemedicine and self monitoring3.60273Improving patient education3.267732Improved methods of IOP assessment3.267732Improved methods of IoP assessment3.267732Improving adherence and drop instillation3.262732Improved endelence for communication3.262732Improved methods of IOP assessment3.267732Improved assessment of visual function <td>Screening early diagnosis avoiding late diagnosis</td> <td>3.886598</td>	Screening early diagnosis avoiding late diagnosis	3.886598
Treatments to restore vision3.835652Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.721494Novel or improved methods of imaging3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597838Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Standardising outcomes3.567010Glaucoma revision surgery3.580701Glaucoma revision surgery3.530822Increasing public awareness3.5257731Improved understanding or integration of structure and function tests3.630818Trabecular meshwork regeneration3.242801Improved evidence for current laser treatments or development of new laser3.31134Solutions for low to middle income settings3.371134Solutions for low to middle income settings3.31134Improved assessment of visual function3.60025Telemedicine and self monitoring3.60025Sustainable healthcare delivery3.200278Improved methods of JOP assessment3.257732Improved methods of JOP assessment3.257732Improved methods of on pristilation3.257732Improved evidence for communication3.60025Better understanding of and treatments for secondary glaucomas3.300278Sustainable healthcare delivery3.260273Improving patient education3.257732Impr	Improved evidence for current treatments	3.835052
Glaucoma registers and real world data3.814433Improved MIGS or better evidence for MIGS3.762887Improved prediction of response to treatment3.721649Novel or improved methods of imaging3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597383Avoiding overtreatment3.587629Quality of life evaluation and improvement3.567010Standardising outcomes3.567010Glaucoma revision surgery3.580622Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.506155Better evidence for treatment larger treatments or development of new laser3.412371Trabecular meshwork regeneration3.422800Improved avidence for current laser treatments or development of new laser3.412371Standardising training in glaucoma3.301733Genetics of glaucoma3.301733Solutions for low to middle income settings3.302026Improved assessment of visual function3.300278Cost effectiveness of glaucoma care3.257732Improved methods of IDP assessment3.257732Improved methores or diry on builty to modulate ocular blood flow3.77228Reduce variability in care3.164948Improved methods of IDP assessment3.267732Improved methods of IDP assessment3.267732Improved methods of IDP assessment3.267732Reduce variability in care3.164948Impro	Treatments to restore vision	3.835052
Improved MIGS or better evidence for MIGS3.76287Improved prediction of response to treatment3.721149Novel or improved methods of imaging3.711140Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597388Avoiding overtreatment3.587629Quality of life evaluation and improvement3.567010Standardising outcomes3.567011Glaucoma revision surgery3.536082Increasing public awareness3.551544Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.205155Better evidence for current laser treatments or development of new laser treatments3.311341Sloutions for low to middle income settings3.371134Sloutions for low to middle income settings3.30278Distandardising training in glaucoma3.30278Sustainable healthcare delivery3.30278Sustainable healthcare delivery3.30278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.17528Reduce variability in care3.16448Improving patient ducation3.257732Improving adherence and drop instillation3.25773Improved assessment of visual function3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to	Glaucoma registers and real world data	3.814433
Improved prediction of response to treatment3.721649Novel or improved methods of imaging3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597388Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.555773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.311341Standardising training in glaucoma3.391753Genetics of glaucoma3.30278Statindardising of and treatments for secondary glaucomas3.30278Improved assessment of visual function3.30278Sustainable healthcare delivery3.30278Cost effectiveness of glaucoma care3.25773Improved understanding or ability to modulate ocular blood flow3.17528Reduce variability in care3.164948Improving adherence and drop instillation3.267732Improving adherence and drop instillation3.267732Improving patient doctor communication3.08274Improved understanding of rare	Improved MIGS or better evidence for MIGS	3.762887
Novel or improved methods of imaging3.711340Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597938Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.5587011Glaucoma revision surgery3.530822Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.31134Solutions for low to middle income settings3.371134Solutions for low to middle income settings3.30278Quatianable healthcare delivery3.30278Sustainable healthcare delivery3.30278Sustainable healthcare delivery3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved definition of glaucoma2.84742Methods to reduce the carbon footprint of treatments2.824742	Improved prediction of response to treatment	3.721649
Treatments with fewer side effects3.670103Sustained release and longer acting treatments3.597938Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.5567011Glaucoma revision surgery3.538082Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.31134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.309278Sustainable healthcare delivery3.309278Sustainable healthcare delivery3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164484Improved understanding of rafe forms of glaucoma3.267732Improved understanding of as formed cular blood flow3.175258Reduce variability in care3.1644948Improved understanding of rafe forms of glaucoma2.84742Methods to reduce the carbon footprint of treatments2.742268	Novel or improved methods of imaging	3.711340
Sustained release and longer acting treatments3.597938Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.551731Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.31134Solutions for low to middle income settings3.371134Improved assessment of visual function3.36022Improved assessment of visual function3.36022Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164484Improved understanding of raf forms of glaucoma2.84742Improved understanding of raf forms of glaucoma3.84772Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164484Improved understanding of raf forms of glaucoma2.845361Improved definition of glaucoma2.845361<	Treatments with fewer side effects	3.670103
Avoiding overtreatment3.587629Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.55773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.31134Solutions for low to middle income settings3.371134Solutions for low to middle income settings3.340206Better understanding of and treatments for secondary glaucoma3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.17528Reduce variability in care3.164484Improved understanding of raft reforms of glaucoma2.84742Mertow duderstanding of and reforms of glaucoma3.267732Improved understanding of ability to modulate ocular blood flow3.17528Reduce variability in care3.1644848Improved understanding of raft forms of glaucoma2.84742Mertow definition of glaucoma2.84742Mertow definition of glaucoma2.84742Methods to reduce the carbon footprint of treatments <td>Sustained release and longer acting treatments</td> <td>3.597938</td>	Sustained release and longer acting treatments	3.597938
Quality of life evaluation and improvement3.587629Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.371134Sloutions for low to middle income settings3.317134Improved assessment of visual function3.360825Telemedicine and self monitoring3.30278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.17528Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved understanding of and treatments of secondary slood flow3.17528Reduce variability in care3.164948Improved understanding of ad treatments or acuar blood flow3.17528Reduce variability in care3.164948Improved understanding of and treatments or acuar blood flow3.17528Reduce variability in care3.164948Improved understanding of rare forms of gl	Avoiding overtreatment	3.587629
Setting appropriate treatment targets3.567010Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Improving patient education3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.17528Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.847361Improved understanding of rare forms of glaucoma2.84742Methods to reduce the carbon footprint of treatments2.742268	Quality of life evaluation and improvement	3.587629
Standardising outcomes3.556701Glaucoma revision surgery3.536082Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.360825Telemedicine and self monitoring3.360825Improved assessment of visual function3.360825Improved assessment of secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of are forms of glaucoma2.84742Methods to reduce the carbon footprint of treatments2.742268	Setting appropriate treatment targets	3.567010
Glaucoma revision surgery3.536082Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improving adherence and drop instillation3.257732Improving natient doctor communication3.08247Improved understanding of rare forms of glaucoma3.164948Improved understanding of rare forms of glaucoma2.845361Improved understanding of rare forms of glaucoma2.842732Methods to reduce the carbon footprint of treatments2.742268	Standardising outcomes	3.556701
Increasing public awareness3.525773Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.84732Maroved understanding of rare forms of glaucoma2.84732Improved understanding of rare forms of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Glaucoma revision surgery	3.536082
Improved understanding of risk factors3.515464Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser3.412371treatments3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Solutions for low to middle income settings3.360825Improved assessment of visual function3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.84742Methods to reduce the carbon footprint of treatments2.742268	Increasing public awareness	3.525773
Identify causes of glaucoma3.505155Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.412371Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Better understanding of and treatments for secondary glaucomas3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.84732Meroving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.84732	Improved understanding of risk factors	3.515464
Better evidence for treatments for angle closure3.474227Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.412371Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.309278Sostainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Identify causes of glaucoma	3.505155
Improved understanding or integration of structure and function tests3.463918Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.412371Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Better evidence for treatments for angle closure	3.474227
Trabecular meshwork regeneration3.422680Improved evidence for current laser treatments or development of new laser treatments3.412371Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Soustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.847362Improved understanding of rare forms of glaucoma2.824732Methods to reduce the carbon footprint of treatments2.742268	Improved understanding or integration of structure and function tests	3.463918
Improved evidence for current laser treatments or development of new laser treatments3.412371Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Trabecular meshwork regeneration	3.422680
Standardising training in glaucoma3.391753Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improved evidence for current laser treatments or development of new laser treatments	3.412371
Genetics of glaucoma3.371134Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Standardising training in glaucoma	3.391753
Solutions for low to middle income settings3.371134Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.082474Improved understanding of rare forms of glaucoma2.845361Improved understanding of rare forms of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Genetics of glaucoma	3.371134
Improved assessment of visual function3.360825Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Solutions for low to middle income settings	3.371134
Telemedicine and self monitoring3.360825Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved understanding of rare forms of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improved assessment of visual function	3.360825
Improving patient education3.340206Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Telemedicine and self monitoring	3.360825
Better understanding of and treatments for secondary glaucomas3.309278Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improving patient education	3.340206
Sustainable healthcare delivery3.309278Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Better understanding of and treatments for secondary glaucomas	3.309278
Cost effectiveness of glaucoma care3.257732Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved efinition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Sustainable healthcare delivery	3.309278
Improved methods of IOP assessment3.257732Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Cost effectiveness of glaucoma care	3.257732
Improving adherence and drop instillation3.257732Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improved methods of IOP assessment	3.257732
Improved understanding or ability to modulate ocular blood flow3.175258Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improving adherence and drop instillation	3.257732
Reduce variability in care3.164948Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Improved understanding or ability to modulate ocular blood flow	3.175258
Improving patient doctor communication3.082474Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.824742Methods to reduce the carbon footprint of treatments2.742268	Reduce variability in care	3.164948
Improved understanding of rare forms of glaucoma2.845361Improved definition of glaucoma2.8224742Methods to reduce the carbon footprint of treatments2.742268	Improving patient doctor communication	3.082474
Improved definition of glaucoma         2.824742           Methods to reduce the carbon footprint of treatments         2.742268	Improved understanding of rare forms of glaucoma	2.845361
Methods to reduce the carbon footprint of treatments 2.742268	Improved definition of glaucoma	2.824742
	Methods to reduce the carbon footprint of treatments	2.742268

# Patient responses (pooled from all countries)

Priority	Mean
Treatments to restore vision	4.495495
Better ways to stop sight loss	4.477477
Finding a cure	4.400000
Improved detection of worsening glaucoma	4.360360
Development of treatments to avoid need for eye drops	4.216216
Better ways to avoid surgery	4.162162
Better medical treatments	4.135135
Treatments to keep patients independent	4.135135
Treatments with fewer side effects	4.135135
Improved diagnostic tests	4.099099
Better understanding of what causes glaucoma and risk factors	4.064220
Genetics of glaucoma	4.036036
Better treatments for children and young patients	4.018018
Better surgical or laser treatments	3.990909
Better delivery of care e g shorter waiting times or less visits	3.954955
Improving visual field tests	3.945946
Methods to treat glaucoma other than by lowering eye pressure	3.918919
Screening early diagnosis avoiding late diagnosis	3.900000
Longer lasting sustained release medications	3.882883
Improved evidence for new surgical options	3.855856
Methods for patients to measure their own eye pressure or monitor their own disease	3.792793
Improving living with glaucoma	3.720721
Improving patient doctor communication	3.702703
Less invasive treatments	3.702703
Drops with fewer side effects	3.693694
Improved ways of identifying glaucoma experts	3.666667
Patient education and self help	3.657658
Improved methods of measuring eye pressure	3.630631
Affordable treatments	3.612613
Improve awareness among public	3.536364
Increasing public awareness	3.486486
Making eye drops easier to use	3.387387
Improving psychological support	3.369369
Register of patients with glaucoma	3.243243
Improving adherence	3.203704

#### Patient responses - Round 1



#### Patient responses - Round 1

	Priority	Frequency
1	Affordable treatments	2
2	Better delivery of care e.g. shorter waiting times or less visits	4
3	Better medical treatments	10
4	Better surgical or laser treatments	11
5	Better treatments	27
6	Better treatments for children and young patients	7
7	Better understanding of what causes glaucoma and risk factors	32
8	Better ways to avoid surgery	1
9	Better ways to stop sight loss	32
10	Development of treatments to avoid need for eye drops	8
11	Drops with fewer side effects	19
12	Finding a cure	10
13	Genetics of glaucoma	4
15	Improve awareness among public	2
16	Improved detection of worsening glaucoma	3
17	Improved diagnostic tests	1

# Round 1 - Patient Responses

18	Improved evidence for new surgical options	1
19	Improved methods of eye pressure assessment	2
20	Improved ways of identifying glaucoma experts	1
21	Improving adherence	1
22	Improving living with glaucoma	1
23	Improving patient-doctor communication	2
24	Improving psychological support	1
25	Improving visual field tests	2
26	Increasing public awareness	10
27	Less invasive treatments	2
28	Longer lasting, sustained release medications	15
29	Making eye drops easier to use	5
30	Methods for patients to measure their own eye pressure or monitor their own disease	7
31	Methods to treat glaucoma other than by lowering eye pressure	1
32	Neuroprotection and treatments that don't rely on lowering eye pressure alone	7
33	Patient education and self-help	23
34	Register of patients with glaucoma	1

35	Screening, early diagnosis, avoiding late diagnosis	51
38	Treatments to keep patients independent	1
39	Treatments to restore vision	47
40	Treatments with fewer side effects	6

# Summary of Round 1 – Clinician Responses



# Summary of Round 1 - Clinician Responses

Priority	Frequency
Artifical intelligence in glaucoma management	26
Associations between neurological disorders and glaucoma	6
Avoiding overtreatment	2
Better evidence for treatments for angle closure	1
Better tools to detect progression and risk of rapid progression	16
Better tools to detect progression and to detect those at high risk of pogression	28
Better understanding of and treatments for exfoliative glaucoma	5
Better understanding of and treatments for pigmentary glaucoma	1
Better understanding of different types of glaucoma	1
Cost effectiveness of glaucoma care	17
Epidemiology of glaucoma	7
Genetics of exfoliation syndrome/exfoliative glaucoma	1
Genetics of glaucoma	27
Glaucoma registers and real world data	7
Glaucoma revision surgery	1
Identify causes of glaucoma	16
Improved assessment of visual function	15
Improved definition of glaucoma	1

Improved diagnosis or monitoring of glaucoma in high myopes	4
Improved evidence for current laser treatments or development of new laser treatments	11
Improved evidence for current surgical treatments	19
Improved evidence for current treatments	14
Improved management of advanced glaucoma	2
Improved methods of IOP assessment	5
Improved MIGS or better evidence for MIGS	39
Improved modulation of wound healing	19
Improved prediction of response to treatment	6
Improved surgical treatments	29
Improved treatments	34
Improved understanding of rare forms of glaucoma	3
Improved understanding of risk factors	10
Improved understanding or ability to modulate ocular blood flow	5
Improved understanding or integration of structure and function tests	10
Improving adherence and drop instillation	14
Improving patient education	3
Improving patient-doctor communication	5
Increasing public awareness	1
Methods to reduce the carbon footprint of treatments	
Methods to reduce the carbon footprint of treatments Neuroprotection and non-IOP treatments	66
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments	66 27
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging	66 27 21
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement	66 27 21 19
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care	1 66 27 21 19 1
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis	1 66 27 21 19 1 29
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets	1 66 27 21 19 1 29 2
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training	1 66 27 21 19 1 29 2 2 1
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings	1 66 27 21 19 1 29 2 1 9
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes	1 66 27 21 19 1 29 2 1 9 5
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising training in glaucoma	1 66 27 21 19 1 29 2 1 9 5 1
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising training in glaucoma         Stopping progression of glaucoma	1 66 27 21 19 1 29 2 1 9 5 1 7
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising training in glaucoma         Stopping progression of glaucoma         Sustainable healthcare delivery	1 66 27 21 19 1 29 2 1 9 5 1 7 7 4
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Stopping progression of glaucoma         Sustainable healthcare delivery         Sustainable release and longer acting treatments	1 66 27 21 19 1 29 2 1 9 5 1 7 4 28
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising raining in glaucoma         Sustainable healthcare delivery         Sustained release and longer acting treatments         Telemedicine and self-monitoring	1 66 27 21 19 1 29 2 1 9 5 1 7 7 4 28 20
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising training in glaucoma         Stopping progression of glaucoma         Sustainable healthcare delivery         Sustained release and longer acting treatments         Telemedicine and self-monitoring         Trabecular meshwork regeneration	1 66 27 21 19 1 29 2 1 9 2 1 9 5 1 7 4 28 20 2
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Standardising training in glaucoma         Sustainable healthcare delivery         Sustainable nealthcare delivery         Sustained release and longer acting treatments         Telemedicine and self-monitoring         Trabecular meshwork regeneration	1 66 27 21 19 1 29 2 1 9 5 1 7 4 28 20 2 2 25
Methods to reduce the carbon footprint of treatments         Neuroprotection and non-IOP treatments         New medical treatments         Novel or improved methods of imaging         QoL evaluation and improvement         Reduce variability in care         Screening, early diagnosis, avoiding late diagnosis         Setting appropriate treatment targets         Simulation in surgical training         Solutions for low to middle income settings         Standardising outcomes         Stopping progression of glaucoma         Sustainable healthcare delivery         Sustained release and longer acting treatments         Telemedicine and self-monitoring         Trabecular meshwork regeneration         Treatments to restore vision	1 66 27 21 19 1 29 2 1 9 2 1 9 5 1 7 4 28 20 2 2 25 9